On May 2021, CELLINK AB (“CELLINK”) entered into an agreement to acquire the German company Nanoscribe Holding GmbH (“Nanoscribe”), an award-winning company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology (“2PP”).
Duff & Phelps, A Kroll Business, acted as financial advisor to CELLINK and provided financial and tax due diligence in connection with the acquisition.
Founded in 2016, CELLINK is a leading bioconvergence company that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq Stockholm under CLNK B.
The medium-sized company develops and produces 3D printers and maskless lithography systems for microfabrication as well as specially developed printing materials and application-specific solution sets. The specialist for additive manufacturing of high-precision structures and objects on the nano-, micro- and mesoscale was founded in 2007 as a spin-off of the Karlsruhe Institute of Technology (KIT). More than 2,500 users and operators at top universities and innovative industrial companies worldwide benefit from the groundbreaking technology and application tailored solutions for 3D Microfabrication. Nanoscribe has created its strong market leading position through high quality engineering and agility to continuously develop its products to meet customers’ high expectations. Nanoscribe expects to diversify its product portfolio further in the near future, to expand the customer base.